Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | YES1 | P07947 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
| ▸ | C5AR1 | P21730 | 4/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.34 |
| ▸ | ESR1 | P03372 | 4/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.34 |
| ▸ | WDR5 | P61964 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929037 | 0.87 | HAVCR2 (0.38) | HAVCR2ABL1LCKYES1SRC | |
| SCHEMBL5928905 | 0.76 | TLR8 (0.47) | — | |
| SCHEMBL5929307 | 0.75 | TLR8 (0.38) | — | |
| SCHEMBL8047208 | 0.65 | NOS1 (0.50) | HAVCR2ESR2ESR1NOS1 | |
| SCHEMBL5928902 | 0.64 | TLR8 (0.43) | — | |
| SCHEMBL5929077 | 0.63 | TLR8 (0.42) | — | |
| SCHEMBL5928964 | 0.63 | TLR8 (0.41) | — | |
| SCHEMBL20850537 | 0.62 | CDK2 (0.43) | ESR2ESR1MAP4K1NOS1 | |
| SCHEMBL3534803 | 0.62 | MAPT (0.52) | MAP4K1NOS1 | |
| SCHEMBL21986879 | 0.61 | NOS1 (0.42) | ESR2ESR1MAP4K1NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | NEUROGEN CORPORATION (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2005007087-A2 | SUBSTITUTED (HETEROCYCLOALKYL)METHYL AZOLE DERIVATIVES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | C5AR1, C5AR2, C3AR1 | HAVCR2 267/4885ABL1 1401/4885LCK 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.